-
2024-514603-34-00
5
2020-03-02
intermediate-risk differentiated thyroid cancer patients
-
2024-510712-75-00
9
2020-02-12
advanced / metastatic
-
2024-514637-37-00
5
2020-02-11
Patients with bone sarcomas other than chordoma, who have no residual
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2023-508561-33-00
7
2019-12-12
Newly diagnosed, stage III or IV amenable to surgery, HPV negative, sq
-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2024-514156-33-00
5
2019-08-20
Patients in remission for granulomatosis with polyangiitis (GPA,
Wegen
-
2024-511862-35-00
4
2019-07-19
Adults with non-contrast-enhancing diffuse brainstem gliomas with non-
-
2023-508072-11-00
5
2019-06-26
Castration-resistant prostate cancer
-
2024-510580-28-00
5
2019-06-05
Middle or low locally advanced resectable rectal carcinoma
-
2023-508302-24-00
4
2019-05-07
Locally Advanced/Metastatic Urothelial Cancer
-
2023-509489-39-00
5
2019-02-05
Resectable, non-metastatic soft-tissue sarcoma (STS)
-
2024-512629-97-00
4
2019-01-23
Patients with locally advanced or metastatic low grade endometrial str
-
2024-514780-26-00
4
2018-10-23
Patients ≤50 years old with high-risk osteosarcoma (defined as metasta
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2023-503629-20-00
9
2018-06-27
Metastatic breast cancer, including triple negative breast cancer (TNB
-
2024-513627-16-01
7
2018-03-28
Colorectal cancer metastatic
-
2024-516110-38-00
5
2018-03-06
Hepatoblastoma and Hepatocellular Carcinoma
-
2024-516810-39-00
4
2018-02-13
Adjuvant therapy after salvage surgery of high risk recurrent head and
-
2023-509318-13-00
6
2018-01-15
Multiple indications
-
2024-515678-29-00
4
2016-11-15
Patients with metastatic tumours (colorectal, non-small cell lung, ren
-
2024-512827-36-00
4
2016-10-17
Penis carcinoma
-
2024-515432-71-00
5
2016-09-13
gastrointestinal stromal tumor
-
2024-514791-40-00
9
2016-08-03
pediatric cancer